Case Report: A Case of Akathisia After Switching From Branded to Generic High-Dose Olanzapine
J Clin Psychiatry 2012;73(4):497
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
As many established atypical antipsychotics lose patent exclusivity, use of generic atypical antipsychotics will expectably rise in light of cost. US Food and Drug Administration (FDA) approval of generic drugs requires demonstration of bioequivalence of a generic agent (specifically, a plasma C and area under the curve [AUC] falling within a 90% confidence interval of 80%–125% of that achieved with a branded formulation) but no required evaluation of efficacy or tolerability. Limited data make it difficult for clinicians to advise patients on when less-expensive generic formulations differ from branded drugs in efficacy or adverse effects.
J Clin Psychiatry 2012; 73(4): 497
© 2012 Physicians Postgraduate Press, Inc.